We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EX9 market cap is 5.98B. The company's latest EPS is USD 0.6853 and P/E is 31.04.
| Year End December 28 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 967.78M | 987.54M | 1.43B | 1.61B | 1.83B |
| Operating Income | 369.47M | 110.06M | 286.67M | 201.48M | 170.89M |
| Net Income | 321.01M | 111.78M | 231.06M | 182.28M | 207.77M |
| Year End December 28 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B |
| Total Liabilities | 199.7M | 258.22M | 405.62M | 583.06M | 678.45M |
| Total Equity | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B |
| Year End December 28 2023 | 2020 | 2021 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 526.96M | 208.98M | 400.8M | 362.61M | 333.32M |
| Investing | -587.25M | -131.22M | -42.88M | -524.41M | -26.96M |
| Financing | 12.55M | -25.13M | -14.8M | 586k | -546.05M |
| Market Cap | 5.98B |
| Price to Earnings Ratio | 31.04 |
| Price to Sales Ratio | 3.52 |
| Price to Cash Ratio | 24.52 |
| Price to Book Ratio | 2.85 |
| Dividend Yield | - |
| Shares Outstanding | 303.19M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.7 (3.49%) |
| Company Name | Exelixis Inc Dl 01 |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.exelixis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
